3
Struggling 23andMe Is Exploring Splitting the DNA Company In Two - Slashdot
source link: https://science.slashdot.org/story/24/02/07/2126204/struggling-23andme-is-exploring-splitting-the-dna-company-in-two
Go to the source link to view the article. You can view the picture content, updated content and better typesetting reading experience. If the link is broken, please click the button below to view the snapshot at that time.
Struggling 23andMe Is Exploring Splitting the DNA Company In Two
Follow Slashdot stories on Twitter
binspamdupenotthebestofftopicslownewsdaystalestupid freshfunnyinsightfulinterestingmaybe offtopicflamebaittrollredundantoverrated insightfulinterestinginformativefunnyunderrated descriptive typodupeerror
Sign up for the Slashdot newsletter! OR check out the new Slashdot job board to browse remote jobs or jobs in your area
Do you develop on GitHub? You can keep using GitHub but automatically sync your GitHub releases to SourceForge quickly and easily with this tool so your projects have a backup location, and get your project in front of SourceForge's nearly 30 million monthly users. It takes less than a minute. Get new users downloading your project releases today!
×
Do you develop on GitHub? You can keep using GitHub but automatically sync your GitHub releases to SourceForge quickly and easily with this tool so your projects have a backup location, and get your project in front of SourceForge's nearly 30 million monthly users. It takes less than a minute. Get new users downloading your project releases today!
In a recent interview with Bloomberg, 23andMe CEO Anne Wojcicki said the company was considering splitting its consumer and therapeutics businesses in an effort to boost its stock price and maintain its listing. From a report: Bloomberg noted that the stock has lost more than 90% of its value since the company went public in 2021 through a SPAC merger. Bloomberg said the therapeutics business could be an attractive asset for a larger healthcare company. The business currently has two drug candidates in clinical trials and just received approval to commence testing for a third. The company's DNA database of more than 14 million customers is one of the world's largest. Currently, 23andMe derives most of its revenue from its consumer business, Bloomberg added.
23andMe's stock has been trading below $1 since December, hurt by revelations that hackers were able to access the personal information of around 50% of its subscribers. The company is also facing mounting litigation over the incident. The company is expected to release its Q4 earnings report after market close on Wednesday.
23andMe's stock has been trading below $1 since December, hurt by revelations that hackers were able to access the personal information of around 50% of its subscribers. The company is also facing mounting litigation over the incident. The company is expected to release its Q4 earnings report after market close on Wednesday.
Recommend
About Joyk
Aggregate valuable and interesting links.
Joyk means Joy of geeK